Lineage Cell Therapeutics Inc (LTS:0HNF)
$ 1.07 0 (0%) Market Cap: 137.84 Mil Enterprise Value: 100.87 Mil PE Ratio: 0 PB Ratio: 2.55 GF Score: 60/100

Lineage Cell Therapeutics, Inc. - Special Call Transcript

May 11, 2020 / 09:00PM GMT
Operator

Ladies and gentlemen, thank you for standing by, and welcome to the Lineage Cell Therapeutics conference call. (Operator Instructions) Please be advised that today's conference call is being recorded. (Operator Instructions)

I'd now like to hand the conference over to your host for today's conference call, Mr. Brian Culley, CEO of Lineage Cell Therapeutics. Thank you. Sir, please begin.

Brian M. Culley
Lineage Cell Therapeutics, Inc. - CEO, President & Director

Well, thank you so much, and thanks, everyone, for joining us today. I think we're going to have a great call. With me today on the line, we're very fortunate to have the time of Dr. Christopher Riemann. Dr. Riemann is an accomplished vitreoretinal surgeon from the Cincinnati Eye Institute and University of Cincinnati School of Medicine. He also is an expert on and a named inventor on the patent for the Orbit SDS device, so a very relevant background. He's also a delightful person who has a great skill at translating the sometimes complicated anatomical matters of the retina into very easy

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot